 LA JOLLA, Calif.--BUSINESS WIRE--Janux Therapeutics, Inc. Nasdaq: JANX Janux, a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the closing of its previously announced initial public offering of 13,110,000 shares of its common stock, which includes 1,710,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of 17.00 per share. Including the option exercise, th 